Therapy of experimental NASH and fibrosis with galectin inhibitors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Traber, Peter G ^a,b   Zomer, Eliezer ^a  

^a Galectin Therapeutics Inc   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD36 ANTIGEN; COLLAGEN; GALECTIN 3; GM CT 01; GR MD 02; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; DRUG POTENCY; EXPERIMENTAL LIVER FIBROSIS; GLOMERULOPATHY; HISTOPATHOLOGY; KIDNEY FIBROSIS; KNOCKOUT MOUSE; LIVER CELL; MACROPHAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, CD36; CARBOHYDRATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; FEMALE; GALECTINS; HEPATIC STELLATE CELLS; KIDNEY; LIVER CIRRHOSIS; MICE; NITRIC OXIDE SYNTHASE TYPE II; PREGNANCY; TIME FACTORS;

EID: 84893191346     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083481     Document Type: Article

References (63)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023. 10.1002/hep.25762 [doi].
2. Caldwell S, Argo C (2010) The natural history of non-alcoholic fatty liver disease. Dig Dis 28: 162-168. 000282081 [pii];10.1159/000282081 [doi].
3. Angulo P (2010) Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 51: 373-375. 10.1002/hep.23521 [doi].
4. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, et al. (2011) The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54: 1208-1216. 10.1002/hep.24491 [doi].
5. Rinella ME (2011) Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology 54: 1118-1120. 10.1002/hep.24634 [doi].
6. Di LS, Sundblad V, Cerliani JP, Guardia CM, Estrin DA, et al. (2011) When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50: 7842-7857. 10.1021/bi201121m [doi].
7. Henderson NC, MacKinnon AC, Farnworth SL, Poirier F, Russo FP, et al. (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103: 5060-5065. 0511167103 [pii];10.1073/pnas.0511167103 [doi].
8. MacKinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, et al. (2012) Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185: 537-546. 201106-0965OC [pii];10.1164/rccm.201106-0965OC [doi].
9. Henderson NC, MacKinnon AC, Farnworth SL, Kipari T, Haslett C, et al. (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298. S0002-9440(10)61796-8 [pii];10.2353/ajpath.2008.070726 [doi].
10. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, et al. (2013) Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 8: e75361. 10.1371/journal.pone. 0075361 [doi];PONE-D-13-22440 [pii].
11. Iacobini C, Menini S, Ricci C, Blasetti FC, Scipioni A, et al. (2011) Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 54: 975-983. S0168-8278(10)00915-3 [pii];10.1016/j.jhep.2010.09.020 [doi].
12. Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, et al. (2006) Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 210: 469-477. 10.1002/path.2065 [doi]. (Pubitemid 44830607)
13. Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, et al. (2008) Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 38: 1241-1251. HEP395 [pii];10.1111/j.1872-034X.2008. 00395.x [doi].
14. Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, et al. (2012) Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. ScientificWorldJournal 2012: 959824. 10.1100/2012/959824 [doi].
15. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, et al. (2013) A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 10.1007/s00795-013-0016-1 [doi].
16. Folch J, Lees M, Sloan Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509.
17. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. 10.1002/hep.20701 [doi]. (Pubitemid 40770284)
18. Kim H, Lee J, Hyun JW, Park JW, Joo HG, et al. (2007) Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 31: 655-662. S1065-6995(06)00303-9 [pii];10.1016/j.cellbi.2006.11.036 [doi].
19. Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456. 10.1146/annurev-pathol-011110-130246 [doi].
20. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, et al. (2010) Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 138: 2477-86, 2486. S0016-5085(10)00324-0 [pii];10.1053/j.gastro.2010.02.051 [doi].
21. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R (2012) NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 220: 287-293. S0021-9150(11)00845-8 [pii];10.1016/j.atherosclerosis.2011.08.041 [doi].
22. Bieghs V, van Gorp PJ, Wouters K, Hendrikx T, Gijbels MJ, et al. (2012) LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 7: e30668. 10.1371/journal.pone.0030668 [doi];PONE-D-11-07471 [pii].
23. Bieghs V, Verheyen F, van Gorp PJ, Hendrikx T, Wouters K, et al. (2012) Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One 7: e34378. 10.1371/journal.pone.0034378 [doi];PONE-D-12-01562 [pii].
24. Bieghs V, Walenbergh SM, Hendrikx T, van Gorp PJ, Verheyen F, et al. (2013) Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int. 10.1111/liv.12170 [doi].
25. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, et al. (2008) Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134: 556-567. S0016-5085(07)02114-2 [pii];10.1053/j.gastro.2007.11.037 [doi].
26. He J, Lee JH, Febbraio M, Xie W (2011) The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood) 236: 1116-1121. ebm.2011.011128 [pii];10.1258/ebm.2011.011128 [doi].
27. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, et al. (2003) Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 14: S264-S270. (Pubitemid 36903938)
28. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, et al. (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180: 2650-2658.180/4/2650 [pii].
29. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11: 811-817. hfp097 [pii];10.1093/eurjhf/hfp097 [doi].
30. Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL, et al. (2010) Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 1800: 181-189. S0304-4165(09)00194-9 [pii];10.1016/j.bbagen.2009.07.005 [doi].
31. Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10: e17. S1462399408000719 [pii];10.1017/S1462399408000719 [doi].
32. Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, et al. (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279: 10841-10847. 10.1074/jbc.M312834200 [doi];M312834200 [pii].
33. Salomonsson E, Carlsson MC, Osla V, Hendus-Altenburger R, Kahl-Knutson B, et al. (2010) Mutational tuning of galectin-3 specificity and biological function. J Biol Chem 285: 35079-35091. M109.098160 [pii];10.1074/jbc.M109. 098160 [doi].
34. Ahmad N, Gabius HJ, Sabesan S, Oscarson S, Brewer CF (2004) Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology 14: 817-825. 10.1093/glycob/cwh095 [doi];cwh095 [pii].
35. Miller MC, Klyosov A, Mayo KH (2009) The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology 19: 1034-1045. cwp084 [pii];10.1093/glycob/cwp084 [doi].
36. Miller MC, Ribeiro JP, Roldos V, Martin-Santamaria S, Canada FJ, et al. (2011) Structural aspects of binding of alpha-linked digalactosides to human galectin-1. Glycobiology 21: 1627-1641. cwr083 [pii];10.1093/glycob/cwr083 [doi].
37. Miller MC, Nesmelova IV, Platt D, Klyosov A, Mayo KH (2009) The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J 421: 211-221. BJ20090265 [pii];10.1042/BJ20090265 [doi].
38. Cederfur C, Salomonsson E, Nilsson J, Halim A, Oberg CT, et al. (2008) Different affinity of galectins for human serum glycoproteins: galectin-3 binds many protease inhibitors and acute phase proteins. Glycobiology 18: 384-394. cwn015 [pii];10.1093/glycob/cwn015 [doi].
39. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176: 778-789.176/2/778 [pii].
40. Ochieng J, Furtak V, Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19: 527-535. 10.1023/B:GLYC.0000014082.99675.2f [doi];5256157 [pii].
41. Lau KS, Dennis JW (2008) N-Glycans in cancer progression. Glycobiology 18: 750-760. cwn071 [pii];10.1093/glycob/cwn071 [doi].
42. Sato S, Hughes RC (1992) Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267: 6983-6990.
43. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230: 160-171. IMR794 [pii];10.1111/j.1600-065X.2009. 00794.x [doi].
44. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, et al. (2008) Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 28: 433-440. ATVBAHA.107.159160 [pii];10.1161/ATVBAHA.107.159160 [doi].
45. Lippert E, Gunckel M, Brenmoehl J, Bataille F, Falk W, et al. (2008) Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clin Exp Immunol 152: 285-297. CEI3618 [pii];10.1111/j.1365-2249.2008.03618.x [doi].
46. Ho MK, Springer TA (1982) Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J Immunol 128: 2281-2286. (Pubitemid 12086524)
47. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230: 160-171. IMR794 [pii];10.1111/j.1600-065X.2009. 00794.x [doi].
48. Stefater JA, III, Ren S, Lang RA, Duffield JS (2011) Metchnikoff's policemen: macrophages in development, homeostasis and regeneration. Trends Mol Med 17: 743-752. S1471-4914(11)00144-4 [pii];10.1016/j.molmed.2011.07.009 [doi].
49. Heymann F, Trautwein C, Tacke F (2009) Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 8: 307-318. IADT-01 [pii].
50. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, et al. (2012) Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 109: E3186-E3195. 1119964109 [pii];10.1073/pnas.1119964109 [doi].
51. Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, et al. (2003) Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 112: 389-397. 10.1172/JCI17592 [doi];112/3/389 [pii].
52. Fujita K, Nozaki Y, Yoneda M, Wada K, Takahashi H, et al. (2010) Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcohol Clin Exp Res 34 Suppl 1: S18-S24. ACER756 [pii];10.1111/j.1530- 0277.2008.00756.x [doi].
53. Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, et al. (2009) Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 39: 963-971. HEP539 [pii];10.1111/j.1872-034X.2009.00539.x [doi].
54. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, et al. (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33: 716-724. S0168-8278(00)80301-3 [pii].
55. Kleinert H, Pautz A, Linker K, Schwarz PM (2004) Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 500: 255-266. S0014-2999(04)00739-3 [pii];10.1016/j.ejphar.2004.07.030 [doi].
56. Dragomir AC, Sun R, Mishin V, Hall LB, Laskin JD, et al. (2012) Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production. Toxicol Sci 127: 609-619. kfs117 [pii];10.1093/toxsci/kfs117 [doi].
57. Dragomir AC, Sun R, Choi H, Laskin JD, Laskin DL (2012) Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J Immunol 189: 5934-5941. jimmunol.1201851 [pii];10.4049/jimmunol.1201851 [doi].
58. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, et al. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151. 54/1/142 [pii];10.1136/gut.2004.042127 [doi].
59. Jiao J, Friedman SL, Aloman C (2009) Hepatic fibrosis. Curr Opin Gastroenterol 25: 223-229.
60. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, et al. (2012) Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 5 Suppl 1: S17. 1755-1536-5-S1-S17 [pii];10.1186/1755-1536-5-S1-S17 [doi].
61. Brenner DA (2009) Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 120: 361-368.
62. Bataller R, Brenner DA (2001) Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21: 437-451. 10.1055/s-2001-17558 [doi]. (Pubitemid 32923771)
63. Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, et al. (2012) Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 302: G439-G446. ajpgi.00257.2011 [pii];10.1152/ajpgi.00257.2011 [doi].